Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPulmonologyHighmark Pennsylvania monoclonal antibody Prior Au…
    Ask Trek AI about this page
    CurrentHighmark PennsylvaniaPolicy N/A

    Outpatient Medical Injectable Monoclonal Antibodies for the Treatment of Asthma and Eosinophilic Conditions Request Form

    Customize your policy alerts

    Sign up for all Highmark Pennsylvania policy alerts

    Know when Highmark Pennsylvania releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Request form and documentation requirements for outpatient medical benefit coverage of monoclonal antibody injectables (e.g., Fasenra, Nucala, Cinqair, Tezspire) for asthma and eosinophilic conditions; intended for ordering providers and facility staff to request prior authorization or medical review.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicyOutpatient Medical Injectable Monoclonal Antibodies for the Treatment of Asthma and Eosinophilic Conditions Request Form
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form with member identifiers, ICD-10 diagnosis, required clinical measures, and fax to 833-619-5745.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5document sections

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6
    named biologic products
    833-619-5745fax

    Coverage Criteria and Indications

    Initial and continuation documentation elements for asthma

    Covered when the requester provides the following documentation elements for initial or continuation authorization for asthma.

    Asthma - core documentation: Document severe asthma status; objective measures of uncontrolled asthma including ACT score or ACQ score, number of exacerbations requiring oral or systemic corticosteroids in the past 12 months, and pre-bronchodilator FEV1 with date of test; list prior and current asthma medications (inhalers, oral, injections) with dose and duration over the past year; indicate eosinophilic phenotype with blood eosinophil count and lab date when applicable; state whether the requested product will be used as add-on maintenance therapy and whether it will be used in combination with other biologics (Fasenra, Cinqair, Nucala, Tezspire, Xolair, Dupixent); document prior biologic trials and any contraindications to listed biologics; mark whether this is a New Start or Continuation of Therapy.see form fields (ACT/ACQ, exacerbations, FEV1)

    These items are requested on the form to support medical necessity determination.

    The form specifically asks whether the member has FIP1L1-PDGFRα kinase–positive HES. A positive result identifies a distinct molecular subtype of hypereosinophilic syndrome and would direct evaluation toward targeted therapies for that mutation rather than standard Nucala eligibility; therefore the presence or absence of this kinase–positive status is queried as part of the eligibility assessment for Nucala.

    Coding and Clinical Measures

    Named product HCPCS codes listed on formHCPCS
    J0517FASENRA
    J2182NUCALA
    J2786CINQAIR
    J2356TEZSPIRE
    ACQ / ACT change threshold
    ACQ/ACT change thresholdDecrease in ACQ-6 score by 0.5 from pretreatment baseline, or increase in ACT score by 3 from pretreatment baseline.
    Context on measurementChange is documented as improvement on the form under clinical improvement from the requested product (compare baseline and current scores).
    Use for continuation decisionsForm asks whether the use of the requested product has resulted in this documented change to support continued therapy.
    Nasal corticosteroid trial duration
    Required durationAt least 8 weeks of nasal corticosteroid use (unless not tolerated or contraindicated).
    IndicationThis trial requirement is specified for CRSwNP prior to Nucala being used as add-on maintenance therapy.

    Provider Submission Requirements and Actions

    Prior Authorization

    Prior Authorization Required

    Prior Authorization Required — complete the request form and fax to the specified number. Include HCPCS/J-code examples when applicable and confirm this is a Medical Benefit request.

    • Fax completed form to 833-619-5745
    • Indicate whether supply is via specialty pharmacy or Buy & Bill
    • Include Date of Service and Facility information as applicable
    • Include ICD-10 diagnosis code(s)
    Documentation Required

    Document Prior Biologic Trials and Combination Use

    Document prior biologic trials, responses, contraindications, and whether combination therapy is planned. Indicate if the request is for a new start or continuation of therapy.

    • List prior biologic therapies tried and whether the member failed or had contraindications

    Definitions and Clinical Thresholds

    Uncontrolled severe asthma — key metrics
    ACT / ACQ scoresForm requests ACT score and ACQ score as part of defining uncontrolled severe asthma (document current scores and compare to baseline).
    Exacerbation historyNumber of exacerbations in the past 12 months requiring oral or systemic corticosteroid treatment (to be reported on the form).
    FEV1 threshold / valuePre-bronchodilator FEV1 must be provided with date of test; form requests baseline and current FEV1 when documenting improvement.
    Overall requirementUncontrolled severe asthma is documented by one or more of these objective measures (ACT/ACQ, exacerbations, FEV1) as captured on the form to support medical necessity.
    HES eligibility items (Nucala)
    Minimum diagnosis duration

    Background and Scope

    This request form supports use of monoclonal antibodies as add-on maintenance therapy for severe or uncontrolled asthma and for specific eosinophilic conditions, including Hypereosinophilic Syndrome (HES). The HES section of the form collects indication-specific items such as duration of diagnosis (≥6 months), exclusion of secondary causes, molecular testing (FIP1L1-PDGFRα kinase status), number of recent flares, baseline blood eosinophil count, and stability on current HES therapy prior to initiating therapy with Nucala.

    Revision History

    as shown on form headerpolicy effective / form publicationLatest

    Outpatient Medical Injectable Monoclonal Antibodies request form for asthma and eosinophilic conditions published for use; includes fax submission instructions (Fax to 833-619-5745) and fields for member/provider identifiers and service date.

    Policy Summary
    PayerHighmark Pennsylvania
    PolicyOutpatient Medical Injectable Monoclonal Antibodies for the Treatment of Asthma and Eosinophilic Conditions Request Form
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit a completed prior authorization form with member identifiers, ICD-10 diagnosis, required clinical measures, and fax to 833-619-5745.
    SourceLink
    On This Page
    Coverage Criteria and IndicationsCoding and Clinical MeasuresProvider Submission Requirements and ActionsDefinitions and Clinical ThresholdsBackground and ScopeRevision History
    DocumentationForm asks the provider to confirm inadequate results to nasal corticosteroids for the specified duration and to attach pertinent clinical information.
  1. Provide dates, doses, and clinical response for prior biologics (improvement, no improvement, adverse events)
  2. Indicate if the requested product will be used as add-on maintenance and/or in combination with other biologics
  3. Specify New Start vs Continuation of Therapy
  4. Documentation Required

    Required Documentation to Accompany Request

    Required documentation must accompany the request form. Provide complete member identifiers, provider and facility information, ICD‑10 code(s), date(s) of service, relevant labs, clinical notes, objective measures, and attachment of prior treatment history.

    • Member identifiers: name, DOB, UMI/Member ID
    • Provider and facility: requesting physician name, NPI, address, office contact, facility name and NPI
    • Clinical information: ICD‑10 diagnosis code(s); indication (e.g., severe uncontrolled asthma, CRSwNP)
    • Objective measures: ACT/ACQ scores, number of exacerbations in past 12 months, pre‑bronchodilator FEV1 with date, blood eosinophil count with date
    • Treatment history: list of medications (name, dose, duration) over the past year; prior biologics tried/failed; response to prior therapy
    • Attachments: pertinent clinical notes, test results, imaging/endoscopy reports, and documentation of inadequate response to prior therapies (e.g., nasal corticosteroids for CRSwNP)
    Denial Risk

    Form Completion and Documentation

    Form completion and supporting documentation must be thorough. Incomplete fields or missing attachments (labs, prior treatment records, objective measures) may delay review or result in denial. Ensure all required fields on the form are completed and all pertinent clinical information is attached before faxing.

    • Do not leave required form fields blank (member identifiers, NPI, ICD‑10, dates)
    • Attach supporting clinical notes, lab values (e.g., eosinophil count), ACT/ACQ scores, FEV1 results, and prior biologic trial documentation
    • Indicate clearly whether request is New Start or Continuation of Therapy
    • Missing or incomplete documentation may result in delayed processing or denial
    HES diagnosis duration of ≥6 months is required on the form.
    Exclude secondary causesForm asks whether there is an identifiable non-hematologic secondary cause of HES (must be absent).
    FIP1L1-PDGFRα statusForm asks whether the member has FIP1L1-PDGFRα kinase–positive HES (negative status is required for eligibility).
    Flare historyAt least 2 HES flares within the past 12 months must be reported on the form.
    Baseline eosinophil countProvide baseline blood eosinophil count (prior to starting Nucala) in cells/microliter as requested on the form.
    Stability on therapyMember should be stable on HES therapy (corticosteroids, immunosuppressive or cytotoxic therapy) for at least 4 weeks before starting Nucala.